Anti Cardiolipin Antibodies IgG at Ayzal Lab

Anti Cardiolipin Antibodies IgG at Ayzal Lab

The Anti Cardiolipin Antibodies IgG test is a highly specialized immunological laboratory investigation designed to detect and quantify IgG class autoantibodies directed against cardiolipin, a key phospholipid component of inner mitochondrial membranes and cellular platelets. At Ayzal Lab in Lahore, Pakistan, this assay is performed using advanced, highly sensitive chemiluminescent immunoassay (CLIA) or enzyme-linked immunosorbent assay (ELISA) technologies. Cardiolipin antibodies are clinically significant autoantibodies closely linked to antiphospholipid syndrome (APS), an autoimmune disorder characterized by recurrent arterial or venous thrombosis and pregnancy-related complications, including recurrent spontaneous miscarriages. By measuring the concentration of IgG antibodies, clinicians can accurately risk-stratify patients presenting with unexplained thrombotic events or obstetric pathologies.

Understanding the presence of these autoantibodies is crucial because they interfere with the normal regulation of the blood coagulation cascade. Under physiological conditions, phospholipids help maintain the fluid balance of blood flow. However, when autoantibodies target these phospholipids, they promote platelet activation, endothelial cell dysfunction, and the inhibition of natural anticoagulants like protein C. This prothrombotic state significantly increases the risk of clot formation in both large vessels and microvasculature. Ayzal Lab provides precise quantification of these antibodies, enabling rheumatologists, hematologists, and obstetricians to formulate targeted therapeutic strategies, such as long-term anticoagulation or antiplatelet therapy, to mitigate life-threatening thrombotic risks.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy and prevent potential analytical interference, patients undergoing the Anti Cardiolipin Antibodies IgG test at Ayzal Lab should follow these preparation guidelines:

• No Fasting Required: Fasting is generally not mandatory for this test; however, patients are advised to avoid excessively fatty meals immediately before sample collection to prevent lipemia in the serum specimen.
• Medication Disclosure: It is critical to inform the laboratory staff and your prescribing physician of all ongoing medications, particularly anticoagulants (such as warfarin, heparin, or direct oral anticoagulants) and immunosuppressive drugs, as these can influence clinical interpretation.
• Hydration: Adequate hydration is highly recommended, as it facilitates easier venipuncture and ensures optimal blood flow during collection.
• Timing of Test: If this test is being performed to confirm a diagnosis of Antiphospholipid Syndrome (APS), it must be repeated at least 12 weeks after the initial positive result to distinguish between transient antibodies (often caused by temporary infections) and persistent autoimmune responses.

During the Procedure

The sample collection process at Ayzal Lab is designed to be quick, safe, and minimally invasive, adhering to strict international clinical laboratory standards:

• Patient Identification and Verification: The phlebotomist will verify your identity using your registration details to ensure absolute sample traceability.
• Venipuncture Site Selection: The patient is seated comfortably, and a suitable vein, typically the median cubital vein in the antecubital fossa of the arm, is selected.
• Sanitization: The skin over the selected vein is thoroughly cleansed with an antiseptic swab (70% isopropyl alcohol) and allowed to air dry to prevent specimen contamination or hemolysis.
• Specimen Collection: A sterile, single-use needle is inserted into the vein, and blood is drawn into a gold-top (serum separator) or red-top vacuum tube.
• Post-Collection Care: The needle is gently withdrawn, and immediate local pressure is applied to the puncture site with a sterile cotton ball to prevent hematoma formation. A small adhesive bandage is then applied.
• Duration and Safety: The entire venipuncture procedure takes less than five minutes. All materials used are strictly sterile and disposable, eliminating any risk of cross-contamination.

When is an Anti Cardiolipin Antibodies IgG Test Performed?

Investigation of Unexplained Venous or Arterial Thrombosis

Physicians frequently request the Anti Cardiolipin Antibodies IgG test when a patient presents with unexplained blood clots, such as deep vein thrombosis (DVT) in the lower extremities or a pulmonary embolism (PE) in the lungs. These conditions often manifest as sudden localized swelling, pain, warmth, or acute shortness of breath. When these thrombotic events occur in young individuals or in the absence of obvious risk factors (such as prolonged immobility, major surgery, or active malignancy), an underlying autoimmune etiology like Antiphospholipid Syndrome must be actively investigated to prevent recurrent, potentially fatal thromboembolic episodes.

Evaluation of Recurrent Pregnancy Loss and Obstetric Complications

This immunological investigation is a cornerstone in evaluating women who experience recurrent, unexplained pregnancy losses, typically defined as three or more consecutive early miscarriages before the 10th week of gestation, or one or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week. It is also indicated in cases of premature births before the 34th week due to severe pre-eclampsia, eclampsia, or placental insufficiency. Cardiolipin antibodies can cause thrombosis within the placental microvasculature, leading to placental infarction, restricted fetal growth, or miscarriage. Identifying these antibodies allows obstetricians to initiate prophylactic low-molecular-weight heparin and low-dose aspirin therapies.

Diagnosis of Antiphospholipid Syndrome (APS)

The primary clinical indication for ordering the Anti Cardiolipin Antibodies IgG test is to establish a definitive diagnosis of Antiphospholipid Syndrome, whether primary or secondary to another systemic autoimmune disease. APS is diagnosed based on specific clinical criteria (thrombosis or pregnancy morbidity) combined with laboratory evidence of persistent antiphospholipid antibodies (including cardiolipin IgG/IgM, anti-beta-2 glycoprotein I, or lupus anticoagulant) detected on two or more occasions at least 12 weeks apart. Confirming APS is vital because it dictates the necessity and duration of long-term therapeutic anticoagulation.

Assessment of Systemic Autoimmune Diseases

Patients diagnosed with systemic lupus erythematosus (SLE) or other connective tissue disorders are frequently screened for anti-cardiolipin antibodies. Approximately 30% to 40% of patients with SLE test positive for these autoantibodies. Knowing a patient’s antibody status is clinically valuable because SLE patients who are positive for cardiolipin IgG have a significantly higher risk of developing secondary APS, characterized by accelerated cardiovascular disease, stroke, renal microangiopathy, and neuropsychiatric manifestations. Regular monitoring helps in preemptive clinical management.

Evaluation of Unexplained Neurological Symptoms

Unexplained neurological events, such as transient ischemic attacks (TIAs), premature ischemic strokes in young adults, atypical migraines, or sudden cognitive decline, warrant an evaluation for antiphospholipid antibodies. Cardiolipin IgG antibodies can promote microvascular thrombosis within the cerebral circulation, leading to focal neurological deficits or multi-infarct dementia. By identifying these antibodies as the underlying cause of neurological compromise, neurologists can prescribe targeted antiplatelet or anticoagulant regimens rather than standard stroke therapies, significantly reducing the risk of recurrent cerebrovascular accidents.

What Does an Anti Cardiolipin Antibodies IgG Test Detect?

The Anti Cardiolipin Antibodies IgG test specifically detects and measures the concentration of IgG-class autoantibodies directed against cardiolipin-protein complexes in the blood. A positive result indicates the presence of these autoantibodies, which can be associated with several clinical conditions and pathological states:

• Primary Antiphospholipid Syndrome (APS): Persistent moderate-to-high titers of IgG cardiolipin antibodies in patients with no other underlying autoimmune disease.
• Secondary Antiphospholipid Syndrome: Presence of these antibodies in patients with established autoimmune diseases, most commonly Systemic Lupus Erythematosus (SLE).
• Increased Risk of Venous Thromboembolism: Highly associated with deep vein thrombosis (DVT), pulmonary embolism, and renal vein thrombosis.
• Increased Risk of Arterial Thrombosis: Associated with premature myocardial infarction (heart attack), ischemic stroke, and peripheral arterial occlusion.
• Obstetric Complications: Linked to recurrent early pregnancy loss, late-term fetal demise, severe intrauterine growth restriction (IUGR), and early-onset pre-eclampsia.
• Transient Positivity due to Infections: Temporary, low-to-moderate levels of these antibodies can be triggered by viral, bacterial, or parasitic infections (such as syphilis, malaria, hepatitis C, or HIV) and typically resolve within a few weeks without causing thrombosis.
• Drug-Induced Autoimmunity: Certain medications, including chlorpromazine, procainamide, and phenytoin, can induce the transient production of anti-cardiolipin antibodies.
• Thrombocytopenia: A low platelet count is frequently observed in patients with positive cardiolipin antibodies, as the antibodies can bind to and accelerate the clearance of platelets.

Turnaround Time and Report Access at Ayzal Lab

At Ayzal Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making and patient peace of mind. The Anti Cardiolipin Antibodies IgG test is processed using fully automated, state-of-the-art immunoassay analyzers to ensure rapid and highly reproducible results. Typically, reports are verified by our consultant pathologists and made available within 24 to 48 hours of sample collection. Patients and referring physicians can conveniently access, download, and print reports online through the secure Ayzal Lab patient portal, or receive them directly via WhatsApp and SMS notifications, eliminating the need for unnecessary travel to the laboratory.

Anti Cardiolipin Antibodies IgG Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-Cardiolipin IgG Antibody Level	Negative (< 15 GPL units)	Positive (≥ 15 GPL units); classified as low, medium, or high positive titers.
Clinical Interpretation	No detectable IgG autoantibodies; low risk for APS-related thrombosis.	Persistent high titers indicate Antiphospholipid Syndrome (APS) if clinical criteria are met.
Coagulation Association	Normal coagulation profile and platelet function.	Prothrombotic state, increased risk of arterial/venous clot formation.
Obstetric Implications	Normal pregnancy progression (low immunological risk).	Increased risk of recurrent miscarriage, pre-eclampsia, and placental insufficiency.
Autoimmune Correlation	No active cardiolipin-related autoimmune activity.	Strong correlation with Systemic Lupus Erythematosus (SLE) or primary APS.
Platelet Count Correlation	Normal platelet count (150,000 – 450,000/µL).	Associated thrombocytopenia (low platelet count) due to antibody-mediated clearance.
Temporal Persistence	Not applicable.	Transient positive (resolves within 12 weeks) vs. Persistent positive (confirms APS).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Ayzal Lab for Anti Cardiolipin Antibodies IgG?

• Experienced Healthcare Professionals: Our laboratory is managed by highly qualified consultant pathologists and skilled technologists specializing in immunology.
• Patient-Focused Care: We prioritize patient comfort and convenience, offering a compassionate environment during sample collection.
• Quality Diagnostic Services: Ayzal Lab adheres to stringent internal and external quality control protocols to ensure absolute accuracy.
• Professional Reporting: All reports are thoroughly verified, providing clear, quantitative data that clinicians can trust.
• Modern Diagnostic Approach: We utilize advanced chemiluminescent immunoassay technology for superior sensitivity and specificity.
• Comfortable Environment: Our collection centers in Lahore are designed to provide a hygienic, stress-free, and comfortable experience.
• Convenient Location: Easily accessible facilities across the city make it simple for patients to visit for diagnostic testing.
• Commitment to Accurate Diagnosis: We are dedicated to delivering timely, precise results to support effective clinical management and patient wellness.